Cargando…
Stage IV Lung Carcinoids: Spectrum and Evolution of Proliferation Rate, Focusing on Variants with Elevated Proliferation Indices
The spectrum and evolution of proliferation rates in stage IV lung carcinoids is poorly defined. In particular, there are limited data on the prevalence and characteristics of tumors exceeding the standard upper proliferative criteria – as defined largely based on early-stage carcinoids – in metasta...
Autores principales: | Rekhtman, Natasha, Desmeules, Patrice, Litvak, Anna M., Pietanza, Maria C., Santos-Zabala, Maria Lauren, Ni, Ai, Montecalvo, Joseph, Chang, Jason C., Beras, Amanda, Preeshagul, Isabel R., Sabari, Joshua K., Rudin, Charles M., Ladanyi, Marc, Klimstra, David S., Travis, William D., Lai, Wei-Chu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746332/ https://www.ncbi.nlm.nih.gov/pubmed/30923345 http://dx.doi.org/10.1038/s41379-019-0248-2 |
Ejemplares similares
-
Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: Napsin A expression and genomic alterations
por: Rekhtman, Natasha, et al.
Publicado: (2017) -
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
por: Rekhtman, Natasha, et al.
Publicado: (2019) -
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019) -
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
por: Drilon, Alexander, et al.
Publicado: (2019) -
A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2016)